{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:02:31Z","timestamp":1783393351083,"version":"3.54.6"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program","doi-asserted-by":"crossref","award":["2021\u201376"],"award-info":[{"award-number":["2021\u201376"]}],"id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fujian Provincial Clinical Research Center for Hematological Malignancies","award":["2020Y2006"],"award-info":[{"award-number":["2020Y2006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thromboembolism (TE) is a serious complication in lymphoma, driving excess morbidity and mortality. Existing prediction tools perform suboptimally in lymphoma-specific settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analysed 790 newly diagnosed lymphoma patients (January 2019\u2013December 2021). Patients were randomly split 7:3 into development and internal-validation cohorts. Forty-eight candidate predictors were screened with LASSO, followed by multivariable Cox modelling to construct a nomogram. Discrimination and calibration were assessed at 6, 12 and 24 months using time-dependent ROC analysis and bootstrap calibration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TE occurred in 77\/790 patients (9.8%). Independent predictors were ECOG performance status, prior venous thromboembolism (VTE), coronary artery disease, central venous catheterisation, and APTT category. The nomogram showed good discrimination: AUCs were 0.813, 0.818 and 0.733 at 0.5, 1.0 and 2.0 years in the development cohort, and 0.724, 0.731 and 0.659 in the validation cohort. Conventional scores performed poorly in this population (e.g., at 1 year ThroLy 0.587 vs. Khorana 0.527). Calibration plots indicated close agreement between predicted and observed risks. Patients who experienced TE had poorer overall survival, with the greatest divergence in survival curves occurring within the first six months after diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This lymphoma-specific model improves TE risk stratification and can inform individualised prophylaxis and early monitoring. External, multi-centre validation is warranted to confirm generalisability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-15162-0","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:13:47Z","timestamp":1762344827000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development and internal validation of a lymphoma-specific nomogram for predicting venous thromboembolism: a retrospective cohort of 790 patients"],"prefix":"10.1186","volume":"25","author":[{"given":"Lili","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nainong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"issue":"3","key":"15162_CR1","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/cncr.27772","volume":"119","author":"AA Khorana","year":"2013","unstructured":"Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism among ambulatory high-risk cancer patients undergoing chemotherapy in the united States. Cancer. 2013;119(3):648\u201355. https:\/\/doi.org\/10.1002\/cncr.27772.","journal-title":"Cancer"},{"issue":"3","key":"15162_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3747\/co.21.1864","volume":"21","author":"E Donnellan","year":"2014","unstructured":"Donnellan E, Kevane B, Bird BR, Ainle FN. Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management. Curr Oncol. 2014;21(3):134\u201343. https:\/\/doi.org\/10.3747\/co.21.1864.","journal-title":"Curr Oncol"},{"issue":"Suppl 2","key":"15162_CR3","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1002\/mpr.267","volume":"17","author":"S Galea","year":"2008","unstructured":"Galea S, Maxwell AR, Norris F. Sampling and design challenges in studying the mental health consequences of disasters. Int J Methods Psychiatr Res. 2008;17(Suppl 2):S21. https:\/\/doi.org\/10.1002\/mpr.267.","journal-title":"Int J Methods Psychiatr Res"},{"issue":"6","key":"15162_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.clml.2014.05.003","volume":"14","author":"R Colombo","year":"2014","unstructured":"Colombo R, Gallipoli P, Castelli R. Thrombosis and hemostatic abnormalities in hematological malignancies. Clin Lymphoma Myeloma Leuk. 2014;14(6):441\u201350. https:\/\/doi.org\/10.1016\/j.clml.2014.05.003.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"26","key":"15162_CR5","doi-asserted-by":"publisher","first-page":"5322","DOI":"10.1182\/blood-2010-01-258624","volume":"115","author":"V Caruso","year":"2010","unstructured":"Caruso V, Di Castelnuovo A, Meschengieser S, et al. Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1 149 events. Blood. 2010;115(26):5322\u20138. https:\/\/doi.org\/10.1182\/blood-2010-01-258624.","journal-title":"Blood"},{"issue":"6","key":"15162_CR6","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/cncr.11623","volume":"98","author":"N Goldschmidt","year":"2003","unstructured":"Goldschmidt N, Linetsky E, Shalom E, Varon D, Siegal T. High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer. 2003;98(6):1239\u201342. https:\/\/doi.org\/10.1002\/cncr.11623.","journal-title":"Cancer"},{"issue":"10","key":"15162_CR7","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.amjmed.2010.05.021","volume":"123","author":"X Zhou","year":"2010","unstructured":"Zhou X, Teegala S, Huen A, et al. Incidence and risk factors of venous thromboembolic events in lymphoma. Am J Med. 2010;123(10):935\u201341. https:\/\/doi.org\/10.1016\/j.amjmed.2010.05.021.","journal-title":"Am J Med"},{"issue":"6","key":"15162_CR8","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","volume":"33","author":"GH Lyman","year":"2015","unstructured":"Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654\u20136. https:\/\/doi.org\/10.1200\/JCO.2014.59.7351.","journal-title":"J Clin Oncol"},{"issue":"10","key":"15162_CR9","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/ajh.24466","volume":"91","author":"D Antic","year":"2016","unstructured":"Antic D, Milic N, Nikolovski S, et al. Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients. Am J Hematol. 2016;91(10):1014\u20139. https:\/\/doi.org\/10.1002\/ajh.24466.","journal-title":"Am J Hematol"},{"issue":"7","key":"15162_CR10","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1002\/cam4.1540","volume":"7","author":"J Rupa-Matysek","year":"2018","unstructured":"Rupa-Matysek J, Brze\u017aniakiewicz-Janus K, Gil L, et al. Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice. Cancer Med. 2018;7(7):2868\u201375. https:\/\/doi.org\/10.1002\/cam4.1540.","journal-title":"Cancer Med"},{"key":"15162_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/10760296211045908","volume":"27","author":"H Abdel-Razeq","year":"2021","unstructured":"Abdel-Razeq H, Ma\u2019koseh M, Mansour A, et al. The application of the ThroLy risk assessment model to predict venous thromboembolism in patients with diffuse large B-cell lymphoma. Clin Appl Thromb Hemost. 2021;27:10760296211045908. https:\/\/doi.org\/10.1177\/10760296211045908.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"15162_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-017-1065-4","volume":"35","author":"J Rupa-Matysek","year":"2017","unstructured":"Rupa-Matysek J, Gil L, Ka\u017amierczak M, Bara\u0144ska M, et al. Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana risk score. Med Oncol. 2017;35(1):5. https:\/\/doi.org\/10.1007\/s12032-017-1065-4.","journal-title":"Med Oncol"},{"issue":"5","key":"15162_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051291","volume":"12","author":"S Hohaus","year":"2020","unstructured":"Hohaus S, Bartolomei F, Cuccaro A, et al. Venous thromboembolism in lymphoma: risk stratification and antithrombotic prophylaxis. Cancers (Basel). 2020;12(5):1291. https:\/\/doi.org\/10.3390\/cancers12051291.","journal-title":"Cancers (Basel)"},{"key":"15162_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.thromres.2019.10.002","volume":"183","author":"JM Byun","year":"2019","unstructured":"Byun JM, Hong J, Yoon SS, et al. Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy. Thromb Res. 2019;183:131\u20135. https:\/\/doi.org\/10.1016\/j.thromres.2019.10.002.","journal-title":"Thromb Res"},{"issue":"2","key":"15162_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2275665","volume":"55","author":"G Liang","year":"2023","unstructured":"Liang G, Li X, Xu Q, et al. Development and validation of a nomogram model for predicting the risk of venous thromboembolism in lymphoma patients undergoing chemotherapy: a prospective cohort study conducted in China. Ann Med. 2023;55(2):2275665. https:\/\/doi.org\/10.1080\/07853890.2023.2275665.","journal-title":"Ann Med"},{"issue":"Suppl 2","key":"15162_CR16","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/S0049-3848(14)50004-7","volume":"133","author":"A Mahajan","year":"2014","unstructured":"Mahajan A, Wun T, Chew H, White RH. Lymphoma and venous thromboembolism: influence on mortality. Thromb Res. 2014;133(Suppl 2):S23\u20138. https:\/\/doi.org\/10.1016\/S0049-3848(14)50004-7.","journal-title":"Thromb Res"},{"issue":"11","key":"15162_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165390","volume":"11","author":"J Yu","year":"2016","unstructured":"Yu J, Li D, Lei D, et al. Tumor-specific D-dimer concentration ranges and influencing factors: a cross-sectional study. PLoS ONE. 2016;11(11):e0165390. https:\/\/doi.org\/10.1371\/journal.pone.0165390.","journal-title":"PLoS ONE"},{"key":"15162_CR18","doi-asserted-by":"publisher","first-page":"e072715","DOI":"10.1136\/bmj-2022-072715","volume":"381","author":"SR Guntupalli","year":"2023","unstructured":"Guntupalli SR, Spinosa D, Wethington S, Eskander R, Khorana AA. Prevention of venous thromboembolism in patients with cancer. BMJ. 2023;381:e072715. https:\/\/doi.org\/10.1136\/bmj-2022-072715.","journal-title":"BMJ"},{"issue":"25","key":"15162_CR19","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.21.7752","volume":"27","author":"C Ay","year":"2009","unstructured":"Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1\u2009+\u20092 predict venous thromboembolism in patients with cancer: results from the Vienna cancer and thrombosis study. J Clin Oncol. 2009;27(25):4124\u20139. https:\/\/doi.org\/10.1200\/JCO.2008.21.7752.","journal-title":"J Clin Oncol"},{"issue":"13","key":"15162_CR20","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1182\/blood-2008-06-165845","volume":"113","author":"SS Adam","year":"2009","unstructured":"Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood. 2009;113(13):2878\u201387. https:\/\/doi.org\/10.1182\/blood-2008-06-165845.","journal-title":"Blood"},{"issue":"4","key":"15162_CR21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s11239-019-01964-0","volume":"49","author":"M Oi","year":"2020","unstructured":"Oi M, Yamashita Y, Toyofuku M, et al. D-dimer levels at diagnosis and long-term clinical outcomes in venous thromboembolism: from the COMMAND VTE registry. J Thromb Thrombolysis. 2020;49(4):551\u201361. https:\/\/doi.org\/10.1007\/s11239-019-01964-0.","journal-title":"J Thromb Thrombolysis"},{"issue":"11","key":"15162_CR22","doi-asserted-by":"publisher","first-page":"16604","DOI":"10.20452\/pamw.16604","volume":"133","author":"B Cosmi","year":"2023","unstructured":"Cosmi B, Legnani C, Libra A, Palareti G. D-Dimers in diagnosis and prevention of venous thrombosis: recent advances and their practical implications. Pol Arch Intern Med. 2023;133(11):16604. https:\/\/doi.org\/10.20452\/pamw.16604.","journal-title":"Pol Arch Intern Med"},{"issue":"6","key":"15162_CR23","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1007\/s11239-024-02977-0","volume":"57","author":"I S\u00e1nchez Prieto","year":"2024","unstructured":"S\u00e1nchez Prieto I, Guti\u00e9rrez Jomarr\u00f3n I, Mart\u00ednez V\u00e1zquez C, et al. Comprehensive evaluation of genetic and acquired thrombophilia markers for an individualized prediction of clinical thrombosis in patients with lymphoma and multiple myeloma. J Thromb Thrombolysis. 2024;57(6):984\u201395. https:\/\/doi.org\/10.1007\/s11239-024-02977-0.","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"15162_CR24","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1055\/a-2207-7715","volume":"8","author":"M Shoji","year":"2024","unstructured":"Shoji M, Yamashita Y, Ishii M, et al. A predictive model for cancer-associated thrombosis in Japanese cancer patients: findings from the J-Khorana registry. TH Open. 2024;8(1):e11\u20138. https:\/\/doi.org\/10.1055\/a-2207-7715.","journal-title":"TH Open"},{"issue":"10","key":"15162_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002883","volume":"16","author":"JF Timp","year":"2019","unstructured":"Timp JF, Braekkan SK, Lijfering WM, et al. Prediction of recurrent venous thrombosis in all patients with a first venous thrombotic event: the Leiden thrombosis recurrence risk prediction model (L-TRRiP). PLoS Med. 2019;16(10):e1002883. https:\/\/doi.org\/10.1371\/journal.pmed.1002883.","journal-title":"PLoS Med"},{"issue":"3","key":"15162_CR26","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1182\/blood-2012-06-433243","volume":"120","author":"JC Souto","year":"2012","unstructured":"Souto JC, Soria JM. Predicting individual risk of venous thrombosis. Blood. 2012;120(3):500\u20131. https:\/\/doi.org\/10.1182\/blood-2012-06-433243.","journal-title":"Blood"},{"issue":"12","key":"15162_CR27","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1161\/CIRCRESAHA.121.318225","volume":"128","author":"ME Colling","year":"2021","unstructured":"Colling ME, Tourdot BE, Kanthi Y. Inflammation, infection and venous thromboembolism. Circ Res. 2021;128(12):2017\u201336. https:\/\/doi.org\/10.1161\/CIRCRESAHA.121.318225.","journal-title":"Circ Res"},{"issue":"9","key":"15162_CR28","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1161\/CIRCRESAHA.116.306853","volume":"118","author":"JH Foley","year":"2016","unstructured":"Foley JH, Conway EM. Cross-talk pathways between coagulation and inflammation. Circ Res. 2016;118(9):1392\u2013408. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.306853.","journal-title":"Circ Res"},{"issue":"6","key":"15162_CR29","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1055\/s-0035-1556724","volume":"41","author":"BA Lwaleed","year":"2015","unstructured":"Lwaleed BA, Kazmi RS, Cooper AJ. Inflammation, endothelial dysfunction, and thromboembolism. Semin Thromb Hemost. 2015;41(6):547\u20138. https:\/\/doi.org\/10.1055\/s-0035-1556724.","journal-title":"Semin Thromb Hemost"},{"key":"15162_CR30","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.critrevonc.2016.01.007","volume":"99","author":"A Saghazadeh","year":"2016","unstructured":"Saghazadeh A, Rezaei N. Inflammation as a cause of venous thromboembolism. Crit Rev Oncol Hematol. 2016;99:272\u201385. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.01.007.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"13","key":"15162_CR31","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1182\/blood-2017-03-743211","volume":"130","author":"Y Hisada","year":"2017","unstructured":"Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood. 2017;130(13):1499\u2013506. https:\/\/doi.org\/10.1182\/blood-2017-03-743211.","journal-title":"Blood"},{"issue":"12","key":"15162_CR32","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1002\/cncr.21496","volume":"104","author":"AA Khorana","year":"2005","unstructured":"Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104(12):2822\u20139. https:\/\/doi.org\/10.1002\/cncr.21496.","journal-title":"Cancer"},{"key":"15162_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1386071","volume":"15","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Zhao Y, Xu M, et al. Role of recombinant human granulocyte colony-stimulating factor in development of cancer-associated venous thromboembolism in lung cancer patients who undergo chemotherapy. Front Immunol. 2024;15:1386071. https:\/\/doi.org\/10.3389\/fimmu.2024.1386071.","journal-title":"Front Immunol"},{"issue":"5","key":"15162_CR34","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10552-016-0742-5","volume":"27","author":"XL Du","year":"2016","unstructured":"Du XL, Zhang Y, Hardy D. Associations between hematopoietic growth factors and risks of venous thromboembolism, stroke, ischemic heart disease and myelodysplastic syndrome: findings from a large population-based cohort of women with breast cancer. Cancer Causes Control. 2016;27(5):695\u2013707. https:\/\/doi.org\/10.1007\/s10552-016-0742-5.","journal-title":"Cancer Causes Control"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15162-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15162-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15162-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:13:48Z","timestamp":1762344828000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15162-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15162"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15162-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"5 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of Fujian Medical University Union Hospital. Owing to the retrospective design and anonymisation of patient data, the requirement for informed consent was waived in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1720"}}